Long-Acting Contraception Rates Rose 49% With No-Cost Policy
The data are particularly important because LARC, which includes intrauterine devices (IUD) and subdermal implants, is the most effective type of contraception, study author Laura Schummers, ScD, assistant professor of health outcomes at the University of British Columbia in Vancouver, told Medscape Medical News.
The research was published on July 28 in The BMJ .
Immediate LARC Increase
'These methods are at least 10 times as effective as other kinds of contraception,' Schummers said. With LARC, 'less than 1% of users become pregnant each year of use.' For comparison, the pill, patch, or ring have failure rates near 6%-9%, she noted. In addition, LARC can last for 3-10 years, and its effectiveness does not depend on the user.
More than 40% of pregnancies worldwide are unintended, including 48% of pregnancies in North America, according to the researchers. They examined the numbers of monthly dispensations for all contraception prescriptions, including LARC, in the years before and after a universal contraception coverage policy was instituted in BC in April 2023. Under this policy, the public insurer pays 100% of prescription costs.
The researchers tracked contraception prescriptions that were given to 859,845 reproductive-aged female residents of BC (age, 15-49 years) between April 1, 2021, and June 30, 2024. They compared these prescriptions with those given to a control group derived from the nine other Canadian provinces that did not dispense contraception for free. Without this no-cost intervention, most Canadian insurance plans require copayments, coinsurance, or annual deductibles, and many don't cover contraception at all.
In April 2023, when the new policy took effect, 'we saw an immediate increase by over 1050 additional dispensations per month,' Schummers said. 'By June 2024, there were almost 1300 additional dispensations per month for LARC that amounted to a 49% increase in what we observed vs what was expected, based on the pre-policy trends. That really tells us there was an unmet need for the most effective forms of contraception and that costs were driving contraceptive choices, as well as contraceptive use overall.'
Upfront costs are likely a barrier to the adoption of LARC, said Schummers. Though prescriptions increased for all forms of contraception, 'we found almost all of the increase in use was concentrated in the LARCs,' she said. That difference likely has to do with cost structure. Even though the contraceptive pill is a monthly payment for years, it is a low payment, typically $20-$25. A low payment per month over years may be perceived as easier to pay than the one-time $350-$450 upfront for LARC, said Schummers.
The findings 'confirm that this was a smart policy decision,' according to Schummers. They also may help encourage the policy's adoption in other provinces.
Canada is 'in a period of evolving discussions about contraception coverage and prescription coverage more generally,' Schummers observed. BC was the first province to make the policy change, and Manitoba, Yukon, and Prince Edward Island have followed suit.
'But the remaining provinces do not yet have an agreement in place,' Schummers said. 'Our study provides timely evidence to support those discussions and to guide decisions to follow what BC has done across all the provinces.'
Promoting LARC Uptake
Commenting on the findings for Medscape Medical News, Dustin Costescu, MD, obstetrician/gynecologist and family planning specialist in Hamilton, Ontario, said that despite LARC methods' many advantages, many barriers limit its uptake. This study demonstrates the magnitude of the financial barrier and the rapid increase in uptake when it is removed, he said.
'Moving the needle on LARC uptake is not an easy task. With millions of BC residents, increasing LARC uptake by 1.9% means tens of thousands of individuals have accessed an IUD or implant where previously they could not. While not captured in this study, that translates to a reduction of unintended pregnancies, unplanned births, and abortion by a magnitude of thousands.'
One of the reasons the federal government has prioritized universal access to contraception is that access to birth control has demonstrated cost savings globally, Costescu said.
'The work of the authors, many of whom are primarily responsible for the work to build universal coverage in BC, cannot be overstated and demonstrates the need and demand for LARC access in Canada,' he said.
The study was supported by the Canadian Institutes of Health Research. Schummers reported having no relevant financial relationships. Costescu reported relationships with Searchlight, Organon, Bayer, and Duchesnay.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Target cookies recalled due to possible contamination with wood pieces, impacting multiple states
So far, no illnesses have been reported. Frosted sugar cookies sold at Target stores across the United States have been recalled because they may contain pieces of wood. The U.S. Food and Drug Administration issued a recall for 803 cases of Favorite Day Bakery frosted sugar cookies sold at Target stores in 20 states and Washington, D.C. Favorite Day is a private label brand sold at Target. The voluntary recall was initiated on July 22, 2025, by Give and Go Prepared Foods Corp in Etobicoke, Canada, which prepared the affected bakery items. Target said it has removed all of the impacted cookies from its store shelves and online, according to a statement sent to NBC Chicago. As of Aug. 14, Target does not have the recall listed on its website. How can I identify which specific cookies are recalled? The affected Favorite Day Bakery frosted sugar cookies are the 10-count packages (Net wt. 13.5 oz.) with lot number 25195 and UPC code 85239-41250 3. 'Best By Date can vary as they are applied by retailer when removed from freezer,' the FDA indicates in the recall. Has anyone gotten sick from the cookies? No illnesses have been reported yet. However, the FDA classified the recall as Class II, which means eating the contaminated cookies 'may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.' Where are the Target stores that sold the affected cookies? The FDA says the affected cookies were distributed to Target stores in the following states and D.C.: Connecticut Delaware Illinois Indiana Kentucky Maine Maryland Massachusetts Michigan Missouri New Hampshire New Jersey New York North Carolina Ohio Pennsylvania Rhode Island Tennessee Vermont Virginia Washington, D.C. I bought the cookies that were recalled. What should I do? Customers who purchased the affected frosted sugar cookies can get a full refund by bringing them to their nearest Target store or by calling Target guest relations at 1-800-440-0680. Solve the daily Crossword
Yahoo
5 hours ago
- Yahoo
Yukon fault thought long dormant could trigger 7.5 magnitude earthquake: new research
New research is sounding the alarm about a major geological fault in the Yukon capable of triggering earthquakes of 7.5 magnitude or more. Known as the Tintina Fault, it has built up structural strain that could lead to a large quake within our lifetime, according to researchers at the University of Victoria. They published their findings earlier this month in the journal, Geophysical Research Letters. The UVic team was led by Ph.D student, Theron Finley. The fault stretches about 1,000 kilometres from British Columbia to Alaska. It was once thought to be inactive for at least 40 million years — since before the last ice age ended. Now scientists say it has a history of large ruptures within the last 2.6 million years and could do so again. An earthquake of 7.5 magnitude could damage the Klondike and Dempster highways, the researchers warn, potentially cutting off Dawson City and nearby communities from critical access routes. The Tintina Fault has not previously been recognized as a hazard within Canada's National Seismic Hazard Model (NSHM), which informs earthquake building codes and engineering standards. However, despite its quiet surface, the researcher warn it is far from dormant. Using high-resolution topographic data gathered by satellites, planes and drones, researchers discovered geological formations along the Tintina Fault, one about 2.6 million years old and another roughly 132,000 years old. They have shifted sideways by approximately 1,000 metres and 75 metres. While this suggests multiple past earthquakes, the exact timing and frequency are not known. Researchers cannot definitively state whether the fault is building pressure or predict when the next earthquake might occur. 'We don't know exactly when these have occurred, so you can't actually then make statements about recurrence periods,' Yukon's Geoscience Research Manager, Jan Dettmer told the Yukon News. He cautioned against making definitive predictions about future seismic events and emphasized the need for additional study to fully understand the fault's earthquake potential. Unlike more active fault lines across the country, the researchers say Tintina was overlooked because faults in the region move very slowly and there are few instruments to detect earthquakes. 'I expect this (research) will trigger many studies in the next few years to much better understand what's going on there,' Dettmer said. To gain a better understanding of how often large earthquakes strike the Tintina fault, Finley said they plan to excavate a paleoseismic trench across it. This would allow the team to examine offset sediment layers and date past quakes, providing a clearer picture of the fault's recurrence rate. These findings will be incorporated into future updates and shared with local governments to improve emergency planning. Mike Pemberton wins Yukon Liberal leadership race, will be territory's 11th premier America's 49th state shows support for Canada that Trump wants to make its 51st Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.
Medscape
8 hours ago
- Medscape
Raynaud Phenomenon Tied to Elevated Cardiovascular Risk
TOPLINE: Individuals with Raynaud phenomenon without underlying systemic autoimmune rheumatic diseases had higher risks for major adverse cardiovascular events (MACE) and venous thromboembolism than did a comparator group with irritable bowel syndrome (IBS), regardless of age. METHODOLOGY: Researchers conducted a retrospective cohort study to examine whether individuals with Raynaud phenomenon experienced cardiovascular outcomes more frequently than those without the condition. They included 30,088 individuals younger than 45 years and 60,145 aged 45 years or older with Raynaud phenomenon without systemic autoimmune rheumatic diseases , identified from electronic health records of centers in North America between March 2005 and March 2025. An equal number of propensity score-matched individuals with IBS were assigned as comparators to both age categories. The researchers chose IBS as a comparator group because, like Reynaud phenomenon, it is common in younger and female individuals. In addition, it is not known to be associated with adverse cardiovascular outcomes. Co-primary outcomes were MACE and venous thromboembolism, evaluated over mean follow-up durations of 4.4-4.9 years across groups. TAKEAWAY: Among individuals younger than 45 years, those with Raynaud phenomenon had higher risks for MACE (hazard ratio [HR], 1.23; 95% CI, 1.07-1.42) and venous thromboembolism (HR, 1.32; 95% CI, 1.20-1.46) than did those with IBS. Similar results were observed among individuals aged 45 years or older, where those with Raynaud phenomenon had higher risks for MACE (HR, 1.17; 95% CI, 1.13-1.20) and venous thromboembolism (HR, 1.20; 95% CI, 1.14-1.26) than those with IBS. Individuals with Raynaud phenomenon had higher risks for secondary outcomes such as stroke, any cardiovascular disease, and pulmonary embolism noted in both age categories. IN PRACTICE: '[This] data substantiates several previous reports of an increased risk of CVD [cardiovascular disease] in individuals with RP [Raynaud phenomenon], and provides further supporting evidence of a similar risk of VTE [venous thromboembolism],' the authors of the study wrote. 'Taken together our findings lend further support to suggest that RP (in the absence of any secondary SARD [systemic autoimmune rheumatic disease]) could be a manifestation of subclinical CVD. Of course, this requires further confirmation including prospective studies,' they added. SOURCE: This study was led by Michael Hughes, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom. It was published online on August 5, 2025, in Seminars in Arthritis and Rheumatism. LIMITATIONS: Diagnostic codes were used for identifying the conditions; however, misclassification bias may be possible. Details such as digital ischemic episodes were not available for individuals with Raynaud phenomenon and age of onset and family history were not assessed. Many oral drug treatments for Raynaud phenomenon are vasodilators also used for systemic hypertension; hence, the primary indication was unclear. DISCLOSURES: One author reported receiving support from the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre. Another author reported receiving support from NIHR Clinical Lectureship, and working at centers supported by Versus Arthritis and NIHR Manchester Biomedical Research Centre. Two authors reported receiving research funding, speaker fees, honoraria, and consultancy fees and having other financial ties with multiple companies including Janssen, Sanofi, and Novartis. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
